Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.53 (sialidase)
 2,694 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Gc-globulin or group-specific component, also known as the vitamin D-binding protein, was investigated by the combined use of electrofocusing and immunofixation. Serum of the Gc 2-2 type was found to contain a single protein band whereas serum of the Gc 1-1 type shows two bands with a lower isoelectric point. The Gc 1-2 type contains all three bands known as Gc-2 (pI 5.10), Gc-1Slow (pI 5.03), and Gc-1Fast (pI 4.95). Each apoprotein shows an anodal shift of about 0.07 pH unit after incubation with an excess of 25-hydroxycholecalciferol. After treatment with sialidase Gc-1Fast focuses in the position of Gc-1Slow, whereas the position of Gc-2 remains unchanged.
 ...
PMID:The heterogeneity of human Gc-globulin. 7 72

Upon removal of its sialic acid or galactose residue, vitamin D-binding protein (DBP) becomes a potent macrophage-activating factor, DBP-MAF. Here we document a new function of DBP-MAF and its parent molecule, DBP, in osteoclast control. We show that all DBPs potently inhibit extracellular Ca2+ (cation) sensing at low nanomolar concentrations with the following rank order of potency: native DBP = sialidase-treated DBP > beta-galactosidase-treated DBP. This attenuation remains unaffected despite co-incubation either with the native DBP ligand, 1,25-dihydroxyvitamin D3, or with an asialoglycoprotein receptor modulator, asialoorosomucoid. Taken together, the results suggest that circulating DBP may play a role in the systemic control of osteoclastic bone resorption, a hitherto unrecognized action of the protein.
 ...
PMID:A possible new role for vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+ sensing at low physiological concentrations. 973 Nov 94